Price still isn’t right for Biogen’s blockbuster drug
HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion
Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.
It is being reimbursed by numerous health systems across Europe - but to varying degrees.
The HSE told Biogen that it would not reimburse Spinraza at the price it was offering.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Full vaccination more effective than a booster campaign, Nphet advisor says
Cathal Walsh says strain-specific top-ups can play a role but primary vaccination is still far more effective
Majority of HSE special budget for reducing waiting lists to go unused this year
The HSE confirmed that just €97m of the €210m fund was projected to be spent by the end of 2021
Health group headed by Irishman fires 1,400 staff over vaccine refusal
Michael Dowling, who runs Northwell Health in New York, thanks majority of staff, ‘who did the right thing and got vaccinated’